The guardrails are off as crypto prices soar. The next crash will hurt.
Hackers stand to gain “a superpower.” Will the crypto industry be ready?
With elevated inflation, income investments that can keep up with the pace of rising prices are crucial.
A bubbling movement to overhaul the Fed is ready to seize the moment. Big changes are in store for the central bank.
Randall W. Forsyth
Dealmaking is in style again under President Donald Trump. Potential takeover targets include C3.ai, Viking Therapeutics, and Lyft.
Even the most fleshed-out trade pacts are light on details, and in some cases there are different interpretations of what was agreed upon.
It has been a lost decade for the entertainment giant. But with TV declines baked in and growth improving, the stock is ready for a new era
Annuities are often complicated, with confusing fee structures, but certain ones can make sense for a portion of your retirement portfolio.
Higher inflation data could soon fuel market volatility. While that can be scary, it pays to stick with your diversified mix of stocks and bonds.
The stock market gains about 10% a year, but your savings may be falling behind. Here’s how to make the most of your 401(k).
The trust fund backing benefits may run dry in seven years. Claiming early still has many drawbacks.
A raid at Louisiana’s Delta Downs illustrates the challenges for businesses—and potentially the U.S. economy—as a result of the Trump administration’s immigration crackdown.
Investing used to be a mostly male domain. Young women are helping to change that.
Dozens of women have repeatedly made our list over the past two decades. It’s a testament to the overall excellence of the advisors we highlight each year.
More than 700 ETFs launched last year, including ones that hold crypto or make leveraged bets on individual stocks like Nvidia. How to make sense of it all.
As the July 9 tariff deadline approaches, expect more deals in coming days, but the drama is far from over. Who is in and who is out—for now.
Last-minute changes to the Republican megabill could benefit big solar and wind developers like Next Era.
There are a lot of factors that can distort blood pressure measurements that you take at home.
President Trump wants an all-American car. U.S. vehicle sales could plunge by as much as 20% if he uses massive levies to get one.
Barron’s has long favored dividend-paying stocks for those seeking income. But bonds now deserve a hard look because they are so attractively priced.
Ed Perks, manager of the 73-year-old Franklin Income Fund, is investing equally in stocks and bonds, often from the same companies. He shares some picks.
Holtec CEO says the plan is to go public within several months. The IPO may be coming at just the right time.
Our annual list features 26 leaders whose deft guidance has put their companies in a stronger competitive position.
Chase’s Sapphire Reserve is charging $795, topping the American Express Platinum card. We look at the slew of rewards premium credit cards offer.
A conversation with Ulrike Hoffmann-Burchardi of UBS Global Wealth Management. Where she sees the next “transformational innovations.”
The lifeblood of the internet is drying up. What the decline of search means for users, companies, and stocks.
“Going Public,” a show hosted by X, allows viewers to invest in start-ups. Two of the featured entrepreneurs have a checkered past, Barron’s found.
Treasury-bill ETFs are rapidly gaining in popularity and challenging money-market funds and bank deposits as a place for retail investors to park cash.
Joe Davis, the firm’s global chief economist, says rates could shoot up if the benefits of AI don’t outweigh the costs of the deficit in coming years.
BARRON’S MAGAZINE: The latest issue features ‘The Next Berkshire’…
These companies are seeking to replicate Warren Buffett’s formula as he prepares to retire. Some have been big winners.
“Tesla without Musk would be a disaster for Tesla shareholders,” a longtime Tesla bull told Barron’s.
This week’s blockbuster IPO of Circle, a leading issuer of stablecoins, shows how crypto is increasingly going mainstream. Here’s how to invest.
U.S. drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be worth up to $25 billion.
The storied company is in a dicey place, plagued by empty shelves, skimpy staff, and messy stores. It’s time for drastic action.
The cruise operator’s stock recently took a hit after cautious management earnings commentary and investor jitters, but it’s well positioned to correct course.4 min read
Successful trial results in the next few years could save thousands of lives and generate billions in new annual revenue for drugmakers.
Boomers Daily 